Study of ZG0895.HCl in Patients With Advanced Solid Tumors
Trial Parameters
Brief Summary
The primary objective of this study is to assess the tolerability and safety of ZG0895.HCl, and to assess the maximum tolerated dose (MTD)/ recommended phase 2 dose (RP2D) of ZG0895.HCl.
Eligibility Criteria
Inclusion Criteria: * Fully understand the study and voluntarily sign the informed consent form(ICF). * Age ≥ 18 and ≤ 75 years old at the time of signing the ICF, either male or female; * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Life expectancy ≥ 3 months. * All adverse events from prior treatment have either returned to baseline or CTCAE 5.0 ≤ Grade 1(except for AEs not constituting a safety risk in the opinions of the investigators, e.g. alopecia, hypothyroidism which can be treated with a hormone replacement, etc). * Both male and female participants (unless postmenopausal, surgical sterilization) and partners must agree to use a reliable form of contraception during the study treatment period and for at least 6 months after the last dose of the study drug. * For lesions that have received radiation therapy, only after the progression of the lesions, they can be considered measurable lesions. Part 1: * Must have at least 1 measurable lesion per Resp